Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose sodium fluoride for bone density in postmenopausal women with low bone mass
ACTRN12607000128493Phase 2Completed
- Sponsor
- Associate Professor Andrew Grey
- Start
- Jun 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium fluoride in osteoporosis and osteopenia (4 arms), sponsored by Associate Professor Andrew Grey. Primary endpoint: Change in lumbar spine bone mineral density. Started Jun 2009; status: completed.
02
Drugs
sodium fluoride
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on ACTRN12607000128493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000128493.